Efficacy and Safety of Rituximab in Children with Refractory Nephrotic Syndrome; A Multicenter Clinical Trial

• Главные авторы: Yo Han Ahn (Автор), Hee Gyung Kang (Автор), Seong Heon Kim (Автор), Kyoung Hee Han (Автор), Hee Yeon Cho (Автор), Jae Il Shin (Автор), Min Hyun Cho (Автор), Young Seo Park (Автор), Su Yung Kim (Автор), Seung Joo Lee (Автор), Hae Il Cheong (Автор), Il-Soo Ha (Автор)
• Формат: ‌
• Опубликовано: The Korean Society of Nephrology, 2014-06-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Rituximab (RTX), anti-CD20 monoclonal antibody, has been proposed as a rescue therapy for refractory nephrotic syndrome (NS) on the basis of favorable clinical observations. While reported efficacy of RTX on refractory RTX is promising, the long-term effect obtained from randomized clinical trial is...